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Abstract: Biomarker-guided clinical trial designs, which focus on testing the effectiveness of a
biomarker-guided approach to treatment in improving patient health, have drawn considerable
attention in the era of stratified medicine with many different designs being proposed in the literature.
However, planning such trials to ensure they have sufficient power to test the relevant hypotheses
can be challenging and the literature often lacks guidance in this regard. In this study, we focus
on the parallel subgroup-specific design, which allows the evaluation of separate treatment effects
in the biomarker-positive subgroup and biomarker-negative subgroup simultaneously. We also
explore an adaptive version of the design, where an interim analysis is undertaken based on a fixed
percentage of target events, with the option to stop each biomarker-defined subgroup early for futility
or efficacy. We calculate the number of events and patients required to ensure sufficient power in
each of the biomarker-defined subgroups under different scenarios when the primary outcome is
time-to-event. For the adaptive version, stopping probabilities are also explored. Since multiple
hypotheses are being tested simultaneously, and multiple interim analyses are undertaken, we also
focus on controlling the overall type I error rate by way of multiplicity adjustment.
Keywords: biomarker; biomarker-guided trial design; clinical research design; personalized medicine;
fixed design; adaptive design; sample size; simulation study; multiplicity issues
1. Introduction
Biomarker-guided treatment is a rapidly developing area of medicine, where treatment choice is
personalised according to an individual’s characteristics e.g., their genetic or other biomarker profile, or
demographics. Stratified medicine, also known as ‘individualized medicine’, ‘personalized medicine’,
or ‘precision medicine’ [1] refers to a population approach aiming to identify a particular subset of
patients that benefit most (or least) from the treatment.
A number of biomarker-guided trial designs have been proposed in the past decade, which test the
effectiveness of a biomarker-guided approach to treatment with the aim of improving patient health.
These designs can be classified into two categories; the adaptive designs thoroughly reviewed in
Antoniou et al. [2] which allow adaptations in trial procedures and/or statistical procedures during the
course of the study without undermining the validity and integrity of the trial; and the non-adaptive
designs which are typically simpler but less flexible and discussed in depth in Antoniou et al. [3].
While such designs have been given significant attention in the literature, there are many challenges
associated with their design, analysis and practical application, which need to be explored further and
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better understood. Key challenges include powering the study adequately, controlling the false-positive
rate, and applying appropriate stopping probabilities.
In the current article we focus on the parallel subgroup-specific design [4–6] which can be explored
more transparently to discuss the above challenges. The parallel subgroup-specific design is used to test
the clinical hypothesis of treatment effect, evaluating the effect of the experimental treatment relative
to a control treatment in both a biomarker-negative and a biomarker-positive subgroup separately.
We also consider an adaptive version of the design, splitting the trial into two stages with the aim of
stopping the study early for either positive or negative outcome. In this adaptive version, the first stage
involves an interim analysis after the pre-specified percentage of events are achieved and a decision
is made whether to stop the trial early for efficacy or futility, or to continue to the second stage of
the study. Futility and efficacy are assessed by comparing the p-values of the observed test statistics
produced at each stage of the design with pre-specified stopping boundaries. The role of an interim
analysis in a clinical trial design is important as it might allow the experimental treatment to be made
available earlier in case of positive results. We have conducted several simulation studies to evaluate a
variety of scenarios.
2. Methods and Findings
2.1. Parallel Subgroup-Specific Design
The parallel subgroup-specific design, a modified version of the marker stratified design, allows for
the evaluation of treatment effects separately in the biomarker-positive subgroup and biomarker-negative
subgroup at the same time [3]. While the marker-stratified design uses the overall significance level a for
each biomarker-defined subgroup separately, the parallel subgroup-specific design controls the overall
type I error rate by splitting the overall significance level a between the two biomarker subgroup tests
such that a = a− + a+ [3]. A graphical illustration of this strategy is given in Figure 1.
J. Pers. Med. 2017, 7, 19  2 of 22 
 
further and better understood. Key challenges include powering the study adequately, controlling 
the false-posi ive rat , and applyi g ap ropriate stopping probabiliti s. 
In the current article we focus on the parallel subgroup-specific design [4–6] which can be 
explored more transparently to discuss the above challenges. The parallel subgroup-specific design 
is used to test the clinical hypothesis of treatment effect, evaluating the effect of the experimental 
treatment relative to a control treatment in both a biomarker-negative and a biomarker-positive 
subgroup separately. We also consider an adaptive version of the design, splitting the trial into two 
stages with the aim of stopping the study early for either positive or negative outcome. In this 
adaptive version, the first stage involves an interim analysis after the pre-specified percentage of 
events are achieved and a decision is made whether to stop the trial early for efficacy or futility, or to 
continue to the second st ge of the tudy. Futility and efficacy are assessed by comparing the p-values 
of the observed test statistics produced at each stage of the design with pre-specified stoppi g 
boundaries. The role of an i terim analysis in a clinical trial design is importa t as it might allow the 
experimental treatment to be made available earlier in case of positive results. We have conducted 
several simulation studies to evaluate a variety of scenarios.  
2. Methods and Findings 
2.1. Parallel Subgroup-Specific Design 
The parallel subgroup-specific design, a modified version of the marker stratified design, allows 
for the evaluation of treatment effects separately in the biomarker-positive subgroup and biomarker-
negative subgroup at the same time [3]. While the marker-stratified design uses the overall 
significance level 𝑎 for each biomarker-defined subgroup separately, the parallel subgroup-specific 
design controls the overall type I error rate by splitting the overall significance level 𝑎  between the 
two biomarker ubgroup tests such that 𝑎 = 𝑎− + 𝑎+ [3]. A graphical illustrat n of this strategy is 
given in Figure 1. 
 
Figure 1. Parallel Subgroup-Specific design. “RAND” refers to randomization of patients. a refers to
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All patients are screened for biomarker status (biomarker positive or biomarker negative)
and then randomized to the experimental or control treatments in the two biomarker subgroups.
Therefore, biomarker status acts as a stratification factor. Consequently, the trial is made up of four
arms, i.e., biomarker-positive patients receiving either the experimental or the control treatment and
biomarker-negative patients receiving either the experimental or the control treatment. A test for
treatment effectiveness (Experimental treatment vs. Control treatment) can therefore be performed in
each biomarker-defined subgroup separately.
Where a trial’s primary outcome is time to some specified event (e.g., time to death), the
hypotheses being tested in the two biomarker subgroups if one assumes exponentially distributed
times can be defined as follows:
(i) Hypothesis being tested (case of two-sided test) in the biomarker negative subgroup
H0,biom− : log(θ−) = 0, where
θ− = HRbiom− =
λE−
λC−
denotes the hazard ratio, and λE− and λC− are the rate parameters of an exponential
distribution for biomarker-negative patients receiving experimental treatment and control
treatment respectively, and
(ii) Hypothesis being tested (case of two-sided test) in the biomarker positive subgroup
H0,biom+ : log(θ+) = 0, where
θ+ = HRbiom+ =
λE+
λC+
refers to the hazard ratio, and λE+ and λC+ are the rate parameters of an exponential
distribution for biomarker-positive patients receiving experimental treatment and control
treatment respectively.
2.1.1. Sample Size Calculation for Time-to-Event Outcomes
For the purpose of undertaking power calculations for this design, we assume that the treatment
effect will be tested using the log-rank test. The total number of events required for the parallel
subgroup-specific design can be calculated by adding up the number of events required in each
biomarker-defined subgroup. Following Mandrekar and Sargent [7], we assume 1:1 randomization,
and therefore the required number of events for each biomarker-defined subgroup can be calculated by
Dj = 4
(
zaj + zβ
)2
[
log
(
θj
)]2 (1)
where j denotes either the biomarker positive subgroup (j = +) or the biomarker negative subgroup
(j = −), zaj , zβ denote the upper aj- and upper β-points respectively of a standard normal distribution
and the required total number of events can be calculated by
D = D− + D+ = 4
(
za− + zβ
)2
[log(θ−)]2
+ 4
(
za+ + zβ
)2
[log(θ+)]
2 (2)
where a− and a+, denote the type I error rates for biomarker-negative and biomarker-positive subgroup
respectively such that a− + a+ = a, and a is the nominal significance level (if one-sided e.g., a = 0.025
in our case) and β corresponds to the type II error rate (it is common across the two subgroups).
One-sided significance levels are used in situations where an alternative hypothesis specifies that the
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treatment benefit in the experimental group is greater than that of the control group. In case that a
two-sided a is used (e.g., a = 0.05), then (2) can be written as
D = D− + D+ = 4
(
za−/2 + zβ
)2
[log(θ−)]2
+ 4
(
za+/2 + zβ
)2
[log(θ+)]
2 .
When more than one hypothesis for the assessment of experimental treatment efficacy is being
tested, it is important to control the familywise error rate (FWER) by adjusting for multiplicity of
testing to ensure that the probability to commit at least one type I error does not exceed the nominal
significance level. To achieve this, a conservative Bonferroni correction method is often used where a is
allocated between the test for the biomarker-negative subgroup and the test for the biomarker-positive
subgroup either equally (i.e., a /2) or unequally, meaning that the significance levels assigned to each
biomarker defined-subgroup then add up to the total significance levela .
The calculation of the total sample size needed for this study is based on the total number of events
and the probability that a subject will get an event prior to the end of the study [8]. Therefore, the
sample size required for subgroup j is,
Nj =
Dj
Prj(event)
(3)
where j refers to the biomarker-defined subgroup, Prj(event) corresponds to the probability of
observing an event in biomarker subgroup j which can be calculated by
Prj(event) = piEPrEj(event) + piCPrCj(event),
with
piE =
R
R + 1
and piC =
1
R + 1
.
piE and piC are the proportions of patients who are randomized to the experimental and control
treatment arm respectively. R is the allocation ratio which is given by the sample size in experimental
arm divided by the sample size in control arm. Here we assume equal allocation between treatment
arms for each biomarker-defined subgroup [9]; hence R = 1 and piE = piC = 0.5. PrEj(event) and
PrCj(event) are the probability of event in the experimental and control treatment arm respectively
in subgroup j. If i now denotes treatment group (either experimental (E) or control (C)) and if one
assumes exponentially distributed times, the probability of an event in treatment arm i of subgroup j
can be calculated by
Prij(event) = 1− 1( log(2)
mij
)
× Tj
×
[
e
−( log (2)mij )×τj − e−(
log (2)
mij
)×(Tj+τj)
]
, (4)
where Tj corresponds to the length in months of the accrual period, during which an homogeneous
Poisson entry process is assumed, of the biomarker-defined subgroup j and τj corresponds to the
follow-up period of the biomarker-defined subgroup j. mij denotes the median survival time of
treatment arm i in biomarker-defined subgroup j where
mE− =
mC−
θ−
(5)
and
mE+ =
mC+
θ+
. (6)
Equation (4) could be generalized to arbitrary, continuous survival functions.
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Using the sample size of each biomarker-defined subgroup, the corresponding accrual rate
(number of patients recruited per month) for subgroup j is arj which can be calculated by
arj =
Nj
Tj
. (7)
2.1.2. Simulation Study 1
The scope of this simulation study is to confirm that we can achieve the desirable power in
each biomarker-defined subgroups under different simulation settings for a time-to-event outcome.
We calculate the required number of events and patients for each biomarker-defined subgroup
(
Dj, Nj
)
from Equations (1) and (3). Different scenarios are considered by varying hazard ratios (θ−, θ+) and
significance levels (a−, a+). In our simulation study, we assume that the biomarker-negative patients
have a worse treatment outcome as compared to the biomarker-positive subgroup. We assume outcome
to be an adverse effect and so the assumed hazard ratio values <1 reflect the fact that the experimental
treatment is superior to the control treatment in both biomarker subgroups. Further, the lower
hazard ratio value assumed for a specific biomarker-defined subgroup reflects a greater treatment
effect in that subgroup. Hence, in all scenarios of hazard ratios, we consider higher θ− than θ+.
More specifically, four scenarios of hazard ratios, i.e., (i) θ− = 0.6 and θ+ = 0.4, (ii) θ− = 0.7 and
θ+ = 0.5, (iii) θ− = 0.8 and θ+ = 0.6, and (iv) θ− = 0.9 and θ+ = 0.7 and three scenarios of significance
levels (i) a− = a+ = 0.0125, (ii) a− = 0.015 and a+ = 0.010, and (iii) a− = 0.010 and a+ = 0.015
are considered. We set the median survival time of biomarker-negative subgroup in control group
(mC−) in Equation (5) at five months and we calculate the corresponding median survival time for the
experimental group in that subgroup. We set the median survival time of biomarker-positive subgroup
in control group (mC+) in Equation (6) at ten months and we calculate the corresponding median
survival time for the experimental group in that subgroup. Additionally, we set the type II error rate at
20%, i.e., β = 0.2 in Equation (1) which corresponds to 80% power (i.e., 1− β = 0.8), length of accrual
period
(
Tj
)
in Equation (4) at 18 months and length of follow-up time
(
τj
)
in Equation (4) at 12 months
for each biomarker-defined subgroup. Study entry times and event times for each biomarker-defined
subgroup are generated as described below.
The time of study entry for participants in each biomarker-defined subgroup is modeled with
a uniform distribution for entry times. More precisely, the entry times of patients recruited into the
biomarker negative subgroup in the first month are assumed by randomly generating ar− (the accrual
rate) numbers from U ∼ Uni f [0, 1]. Similarly, ar+ numbers are generated from U ∼ Uni f [0, 1]
to obtain study entry times of patients recruited into the biomarker positive subgroup during the
first month. To obtain study entry times for those in the biomarker negative and biomarker positive
subgroups during the second month, a further ar− and ar+ numbers respectively are randomly
generated from U ∼ Uni f [1, 2]. The accrual continues until the assumed accrual period Tj. Thus, in
the Tjth month, study entry times are generated from U ∼ Uni f
[
Tj − 1, Tj
]
. At the end of the accrual
period N+ and N− participants in total have been recruited.
Event times are generated from an exponential distribution assuming hazard rate λij for jth
biomarker-defined subgroup receiving treatment i. The values of λij can be determined by
Sij
(
mij
)
= exp
(−λij ×mij) = 0.5,
where mij are corresponding median survival times, and Sij
(
mij
)
is the exponential median survival
probability for subgroup j and treatment i. By solving Sij
(
mij
)
for λij gives
λij =
ln 2
mij
.
J. Pers. Med. 2017, 7, 19 6 of 19
We assume patients are not lost to follow-up during the study, and hence any censoring in both
biomarker-defined subgroups is due to the event occurring after a cutofftime. The cutoff time refers to
the time after study start at which a pre-specified number of events Dj for each biomarker-defined
subgroup has been reached. A time tij (i.e., sum of accrual time and follow-up time) is generated for
each patient, and if tij is greater than the cutoff time then it is assumed that the patient encountered
the event at tij, otherwise the patient’s event time is censored at tij.
One-sided p-values for treatment effect in each biomarker-defined subgroup are computed using
the log-rank test. One-sided p-values are considered because we assume that the treatment benefit in
the experimental group is greater than that in the control group.
2.1.3. Results from Simulation Study 1
The results are drawn from 10,000 iterations. The simulated power of each biomarker-defined
subgroup is preserved approximately at 80% across all scenarios of hazard ratios and significance
levels. The accrual rates and the number of events and patients to reach the nominal level of power
(80%) corresponding to different scenarios of hazard ratios and significance levels are presented in
Table S1 provided in Supplementary Materials, File S. The power for each biomarker-defined subgroup
yielded from the simulation study is also presented. Figure 2A–C illustrates the required number of
events for each biomarker-defined subgroup versus the corresponding hazard ratio for each of the
three scenarios of significance levels. Figure 2D–F illustrates the required number of patients of each
biomarker-defined subgroup versus the corresponding hazard ratio for each of the three scenarios
of significance levels. As expected, the number of events and therefore the sample size required for
each biomarker-defined subgroup increases with the increase of the corresponding hazard ratio at the
same significance level. Furthermore, at each scenario of hazard ratio, we can achieve a smaller sample
size and necessary number of events for each biomarker-defined subgroup with a larger significance
level (for example, when HR scenario (i) θ− = 0.6 and θ+ = 0.4, and when a+ = 0.015, we achieve the
smallest necessary number of events and sample sizes).
From Table S1, and more clearly from Figure 2A–F, it can be seen that for each scenario of hazard
ratios, the required number of events and patients in the biomarker-negative subgroup is greater than
in biomarker-positive subgroup.
Figure 3A,B represents the required number of events which achieve 80% power versus the
hazard ratio for each of the three scenarios of significance levels in each biomarker-defined subgroup
separately. Figure 3C,D represents the required number of patients which achieve 80% power versus
the hazard ratio for each of the three scenarios of significance levels in each biomarker-defined
subgroup separately. The corresponding numerical results are presented in Table S1.
It can be seen that for all scenarios of hazard ratios, the highest value of the number of events
and patients in the biomarker-negative subgroup and in the biomarker-positive subgroup is given
by a− = 0.010 and a+ = 0.010 for negative and positive patients respectively and the lowest value is
given by a− = 0.015 and a+ = 0.015 for negative and positive patients respectively.
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2.2. An Adaptive Version of the Parallel Subgroup-Specific Design
We explore a two-stage adaptive design starting with the parallel assessment of treatment effect in each
biomarker-defined subgroup. In the first stage an interim analysis is included where each biomarker-defined
sub-group can stop early for futility or efficacy. The interim analysis is based on a fixed and pre-specified
percentage of target events. In case that we do not stop after the first stage due to early efficacy or
futility, the trial continues to the second stage, testing the efficacy of the experimental treatment in each
biomarker-defined subgroup separately. A graphical illustration of this strategy is given in Figure 4.
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Figure 4. Adaptive parallel subgroup-specific design. “RAND” refers to randomization of patients.
D1+ and D1− correspond to the target number of events of the biomarker-positive subgroup and
biomarker-negative subgroup respectively at the first stage of the study. D+ and D− correspond
to the total required number of events of the bi marker-positive subgroup nd biomarker-negative
subgroup respectively which are planned according to the non-adaptive approach. D2+ and D2−
correspond to the number of events of the biomarker-positive subgroup and biomarker-negative
subgroup respectively at the second stage of the study.
Adaptive designs differ from fixed designs in that they permit the performance of interim analyses
during the course of the study leading to adaptations of hypotheses which are under investigation.
Results from interim analyses are used to make a decision regarding the trial. Several sources of
multiplicity problems can arise in the conduct of adaptive trial designs resulting in the inflation of
the overall type I error rate (probability of a false positive result). One of the sources of type I error
inflation is the adaptation of design and analysis features with combination of information across
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trial stages [10]. Hence, alpha-adjustment (i.e., adjustment of the alpha level at each interim analysis
so that the overall type I error rate remains at the desired level) is needed so that the overall type I
error rate remains under control. A variety of methods for the control of type I error rate in adaptive
designs have been proposed which are thoroughly summarized by Chang [11]. Our study is based
on a flexible and general approach to adaptive designs for a-adjustment proposed by Chang [12] in
which the test statistic of the final analysis is defined as the sum of the unadjusted stagewise p-values
(pl). More precisely, at the kth stage of an adaptive design, the test statistic which can be viewed as
cumulative evidence against the null is given by
T′k =∑kl=1 pl , k = 1, . . . , L =: “maximum stage”.
Before conducting the two-stage design, pre-specification of stopping rules and stopping
boundaries for efficacy and futility are needed. Stopping probabilities (i.e., rejection probabilities)
which are calculated based on the stopping boundaries, are essential operating characteristics of
adaptive designs and they are classified into two types. The first type is the so-called ‘efficacy stopping
probability’, which refers to the unconditional probability of rejecting the null hypothesis of no
treatment effect, thus the trial stops in order to claim efficacy. The second type is the so-called ‘futility
stopping probability’, which refers to the unconditional probability of not rejecting the null hypothesis
of no treatment effect, thus the trial stops in order to claim futility. Hence, the following stopping
boundaries should be chosen: (i) the early efficacy stopping boundaries in stage 1, i.e., e1− and e1+
for biomarker-negative and biomarker-positive patients respectively, (ii) the early futility stopping
boundaries in stage 1, i.e., b1− and b1+ for biomarker-negative and biomarker-positive patients
respectively, and (iii) the final efficacy stopping boundaries, e2− and e2+ for biomarker-negative and
biomarker-positive patients respectively.
If there is prior belief that the experimental treatment is of strong benefit to patients, then the trial
should be designed without early futility stopping (i.e., we need to set a larger value for b1− and/or
b1+). When early efficacy stopping is allowed (e.g., to allow possibility of making treatment available
to patients earlier or to allow possibility of unnecessary treatment exposure or unnecessary trial costs),
then the trial should be designed with a large value of e1− and/or e1+.
After the appropriate choice of e1−, e1+ and b1−, b1+, we can solve for the final efficacy stopping
boundaries, i.e., e2−, e2+ with reference to Chang et al.’s method, based on the sum of p-values.
More precisely, in a clinical trial with k interim analyses, the stopping boundary can be derived by
calculating the rejection probability under the null hypothesis which takes into account the stopping
rules described below. The rejection probability at the kth stage is defined by ψk(ek), where
ψk(t′) = Pr(e1 < T′1 < b1, . . . , ek−1 < T′k−1 < bk−1, T′k < t′)
=
∫ b1
e1
. . .
∫ bk−1
ek−1
∫ t′
−∞ fT′1 ...T′k (t
′
1, . . . t′k)dt′kdt′k−1 . . . dt′1
(8)
where t′ ≥ 0, t′ l(l = 1, . . . , k) is the test statistic at the lth stage, and fT′1 ...T′k is the joint probability
density function of T′1, . . . T′k. The stopping rules for futility can be either binding or non-binding.
In the non-binding rule the possibility of stopping early for futility will not be considered in the
decision of the efficacy stopping boundary whereas in the binding category the futility rule is taken
into account when making inference. As it is stated by Chang [11], the regulatory bodies currently
adopt the non-binding futility rule in order to ensure that the familywise type I error rate is controlled
regardless of whether a decision is made to continue the trial despite a futility boundary being crossed.
For this reason, we set b1− = e2− and b1+ = e2+. Based on Equation (8), according to Chang [12] the
final efficacy stopping boundaries can be found by
e2 =
√
(a− e1) + e1,
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where e1 < a and a refers to the level of significance. In our case, the final efficacy stopping
boundaries for each biomarker-defined subgroup with non-binding futility rule can be found by
the following formulations,
e2− =
√
(a− − e1−) + e1−,
e2+ =
√
(a+ − e1+) + e1+,
where e1− < a− and e1+ < a+.
For the biomarker-negative subgroup of the two-stage adaptive design which tests the efficacy of
the experimental treatment, the stopping rules are the following,
Stage 1 :

Reject the null hypothesis (stop for efficacy) if T′1− ≤ e1−
Do not reject the null hypothesis (stop for futility) if T′1− > b1−
Continue to the second stage if e1− < T′1− ≤ b1−
where 0 < e1− < b1− ≤ 1 and T′1− refers to the log-rank test statistic in the biomarker-negative
subgroup at the first stage of the study,
Stage 2 :
{
Reject the null hypothesis (stop for efficacy) if T′2− ≤ e2−
Do not reject the null hypothesis (stop for futility) if T′2− > e2−
where T′2− refers to the log-rank test statistic in the biomarker-negative subgroup at the second stage
of the study.
For the biomarker-positive subgroup of the two-stage adaptive design which tests the efficacy of
the experimental treatment, the stopping rules are the following,
Stage 1 :

Reject the null hypothesis (stop for efficacy) if T′1+ ≤ e1+
Do not reject the null hypothesis (stop for futility) if T′1+ > b1+
Continue to the second stage if e1+ < T′1+ ≤ b1+
where 0 < a1+ < b1+ ≤ 1 and T′1+ refers to the log-rank test statistic in the biomarker-positive
subgroup at the first stage of the study,
Stage 2 :
{
Reject the null hypothesis (stop for efficacy) if T′2+ ≤ e2+
Do not reject the null hypothesis (stop for futility) if T′2+ > e2+
where T′2+ refers to the log-rank test statistic in the biomarker-positive subgroup at the second stage
of the study.
We now assume the interim fraction or information fraction for the biomarker-negative subgroup
to be f− which refers to a specific proportion of the required total number of events in the
biomarker-negative subgroup, and the interim fraction for the biomarker-positive subgroup be f+
which refers to a specific proportion of the required total number of events in the biomarker-positive
subgroup. Using these interim fractions, we calculate the target number of events for each subgroup at
the interim stage (stage 1), to be:
D1− = D− × f−,
D1+ = D+ × f+,
for negative and positive patients respectively. The log-rank test statistics of each biomarker-defined
subgroup at the first stage (interim analysis) are based on D1−, D1+ and given by
T′1− =
√
Dˆ1−
4
× [log(θˆ−)] ∼ N(√D1−4 × [log(θ−)], 1
)
,
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T′1+ =
√
Dˆ1+
4
× [log(θˆ+)] ∼ N(√D1+4 × [log(θ+)], 1
)
,
for the biomarker-negative subgroup and biomarker-positive subgroups respectively. One-sided
p-values corresponding to the observed values t′1− and t′1+ of the test statistics of each
biomarker-defined subgroup in stage 1 are given by
p1− = Pr
(
T′1− ≥ t′1−
∣∣H0,biom−),
p1+ = Pr
(
T′1+ ≥ t′1+
∣∣H0,biom+),
for the biomarker-negative subgroup and biomarker-positive subgroups respectively.
In the first interim analysis, the test statistic is equal to the p-value at stage 1; hence in our
simulation study we proceed with the following rules: If p1− > b1− or/and p1+ > b1+ then the study
which is testing the efficacy of the experimental treatment in biomarker-negative subgroup and/or
biomarker-positive subgroup is stopped for futility at stage 1. If p1− ≤ e1− and/or p1+ ≤ e1+ then
the study which is testing the efficacy of the experimental treatment in biomarker-negative subgroup
and/or biomarker-positive subgroup is stopped for efficacy at stage 1. Otherwise, if e1− < p1− ≤ b1−
and/or if e1+ < p1+ ≤ b1+, the study which is testing the treatment effect in each biomarker-defined
subgroup continues to the second stage.
The log-rank test statistics of each biomarker-defined subgroup at the second stage of the study
are given by
T′′ 2− =
√( ˆD− − D1−)
4
× [log (θˆ−)] ∼ N(√ (D− − D1−)4 × [log(θ−)], 1
)
,
T′′ 2+ =
√( ˆD+ − D1+)
4
× [log (θˆ+)] ∼ N(√ (D+ − D1+)4 × [log(θ+)], 1
)
,
for the biomarker-negative subgroup and biomarker-positive subgroups respectively. One-sided
p-values corresponding to the observed values t′′ 2− and t′′ 2+ of the test statistics of each
biomarker-defined subgroup in stage 2 are given by
p2− = Pr
(
T′′ 2− ≥ t′′ 2−
∣∣H0,biom−),
p2+ = Pr
(
T′′ 2+ ≥ t′′ 2+
∣∣H0,biom+),
for the biomarker-negative subgroup and biomarker-positive subgroup respectively. The test statistic
of the final analysis for each biomarker-defined subgroup is based on the sum of stagewise p-values
and can be given by
T′− = p1− + p2−,
T′+ = p1+ + p2+,
for the biomarker-negative subgroup and biomarker-positive subgroup respectively.
2.2.1. Simulation Study 2
To investigate the effect of introducing an adaptive element to our study design, we have
conducted a second simulation study which is performed by using the R statistical software
(R Foundation for Statistical Computing, Vienna, Austria). To do this we assume the same total number
of events and patients as we did for Simulation Study 1 (Section 2.1.2) where our design was not
adaptive, therefore making the same assumptions regarding significance levels for biomarker-negative
and biomarker-positive subgroups (a−, a+), hazard ratios (θ−, θ+), median survival time in control
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group (mC−, mC+), accrual period (T−, T+) and follow-up period (τ−, τ+) as we did previously.
Therefore we assume accrual time
(
Tj
)
to be 18 months for both subgroups, follow-up time
(
τj
)
to
be 12 months for both subgroups and consider the following four different scenarios for the hazard
ratios, (i) θ− = 0.6 and θ+ = 0.4, (ii) θ− = 0.7 and θ+ = 0.5, (iii) θ− = 0.8 and θ+ = 0.6, and
(iv) θ− = 0.9 and θ+ = 0.7. For each scenario of hazard ratios we again assume three different
scenarios for significance levels for the biomarker-negative and biomarker-positive subgroups, i.e.,
(i) a− = a+ = 0.0125, (ii) a− = 0.015 and a+ = 0.010, and (iii) a− = 0.010 and a+ = 0.015. For each
hazard ratios and significance level combination explored previously, we test the implication of
different percentages of the information fraction. The different information fractions considered are as
follows: (i) f− = f+ = 25%, (ii) f− = f+ = 50%, and (iii) f− = f+ = 75%. Our aim is to explore the
impact of these different information fractions on study power as well as on the stopping probabilities
for futility (FSPj) and efficacy (ESPj).
In our simulation study for all the scenarios of hazard ratios for each biomarker-defined subgroup
we used a high value of early efficacy stopping boundaries, i.e., e1+, e1− and thus a high value of
early futility stopping boundaries, i.e., b1+, b1− as it is believed that the experimental treatment is
promising. Thus, for the three cases of significance levels for each biomarker-defined subgroup we
have set the following stopping boundaries:
(i) when a− = a+ = 0.0125,
for e1+ = 0.0080 we get b1+ = e2+ =
√
(a+ − e1+) + e1+ = 0.1029,
for e1− = 0.0070 we get b1− = e2− =
√
(a− − e1−) + e1− = 0.1129,
(ii) when a− = 0.015 and a+ = 0.010,
for e1+ = 0.0080 we get b1+ = e2+ =
√
(a+ − e1+) + e1+ = 0.0527,
for e1− = 0.0070 we get b1− = e2− =
√
(a− − e1−) + e1− = 0.0964,
(iii) when a− = 0.010 and a+ = 0.015,
for e1+ = 0.0080 we get b1+ = e2+ =
√
(a+ − e1+) + e1+ = 0.0917,
for e1− = 0.0070 we get b1− = e2− =
√
(a− − e1−) + e1− = 0.0618.
In all cases we have used a slightly lower value for e1− (i.e., 0.007) assuming that it is believed
that the experimental treatment is less promising in biomarker-negative subgroup as compared to the
biomarker-positive subgroup.
Different values of stopping boundaries could be used for each assumed scenario of hazard
ratios and significance levels based on how promising the experimental treatment seems to be in each
subgroup. However, for simplicity, in our study we set only one value of e1+ for biomarker-positive
subgroup and only one value of e1− for biomarker-negative subgroup in all cases of hazard ratios.
The general efficiency related to the cost and time of the trial can be seen from the expected number
of events and expected sample size of the trial which are calculated by using the futility and efficacy
stopping probabilities. The expected sample size is defined by Chang [11] as a function of the effect
size and its uncertainty, which are unknown. Hence, apart from the stopping probabilities and power,
this simulation study also provides the average expected number of events for each biomarker-defined
subgroup (Dexp− , D
exp
+ ). Based on the futility (FSPj) and efficacy stopping probabilities (ESPj), we also
calculate the average expected sample size for each biomarker-defined subgroup, i.e.,
Nexp− = [(ESP− + FSP−)× N1−] + {[1− (ESP− + FSP−)]× N−},
Nexp+ = [(ESP+ + FSP+)× N1+] + {[1− (ESP+ + FSP+)]× N+},
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for negative and positive patients respectively. Assuming that we have constant accrual, we can calculate
the expected duration of the trial for testing the treatment effect in each biomarker-defined subgroup, i.e.,
Texp− = [(ESP− + FSP−)× (T− + τ−)× f−] + {[1− (ESP− + FSP−)]× (T− + τ−)},
Texp+ = [(ESP+ + FSP+)× (T+ + τ+)× f+] + {[1− (ESP+ + FSP+)]× (T+ + τ+)},
for negative and positive patients respectively.
2.2.2. Results from Simulation Study 2
Table 1 in the main manuscript and Tables S2–S4 in Supplementary Materials (File S) provide the
simulation results drawn from 10,000 iterations for each scenario of hazard ratios and significance
levels, for each different assumed percentage of information fraction, i.e., (i) f− = f+ = 25%,
(ii) f− = f+ = 50%, and (iii) f− = f+ = 75%. We report the expected number of events and patients,
expected total study duration, futility stopping probability, efficacy stopping probability and total
power of the study in additional to the required number of patients and events (as presented in Table
S1 for the fixed Parallel Subgroup-Specific design).
From Table 1 and Tables S2–S4, it can be seen that the futility stopping probability of each
biomarker-defined subgroup at each significance level decreases when the percentage of information
fraction increases. On the contrary, the efficacy stopping probability, the total power of the study, the
sample size and the number of events increase with the increase of the information fraction.
When the interim fraction is set to 25% of the required total number of events, the simulation results
indicate that the trial is underpowered. When the interim fraction is based on 50% of the required total
number of events we still do not have a gain in power compared to the nominal level 80%, however, it
achieves approximately 73% and 70% power in biomarker-negative and biomarker-positive subgroup
respectively in all scenarios of hazard ratios when a− = a+ = 0.0125. When the interim fraction
is based on 75% of the required total number of events, we can achieve higher level of power, i.e.,
approximately 77% and 76% power in biomarker-negative and biomarker-positive subgroup respectively
in all scenarios of hazard ratios when a− = a+ = 0.0125. These results for the first scenario of hazard
ratios are graphically represented in Figure 5 (main manuscript). The results for the remaining scenarios
of hazard ratios are graphically represented in Figures S1–S3 in Supplementary Materials, File S.
Figure 6 shows the expected number of events and patients of the adaptive parallel
subgroup-specific design and the required number of events and patients of the fixed parallel
subgroup-specific design for each biomarker-defined subgroup versus the corresponding hazard
ratios for the first level of information fraction (i.e., 25%). Figures S4 and S5 provided in the
Supplementary Materials (File S) show the expected number of events and patients of the adaptive
parallel subgroup-specific design and the required number of events and patients of the fixed parallel
subgroup-specific design for each biomarker-defined subgroup versus the corresponding hazard
ratios for the second and third level of information fraction (i.e., 50%, 75%). Figure 6 and Figures S4
and S5 show that the expected number of events for both biomarker-defined subgroups in all cases
of hazard ratios is lower than the required number of events. Additionally, in all cases of interim
fraction and significance levels, both the required and the expected number of events are greater
in biomarker-negative subgroup as compared to the biomarker-positive subgroup. Furthermore,
they show that the expected number of patients for both biomarker-defined subgroups in all cases
of hazard ratios is lower than the required number of patients. In addition, in all cases of interim
fraction and significance levels, both the required and the expected number of patients are greater in
biomarker-negative subgroup as compared to the biomarker-positive subgroup.
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Table 1. Results for expected number of events and patients, expected total study period, futility stopping probability, efficacy stopping probability and power of
a two-stage design in scenario 1 of hazard ratios for different percentages of information fraction. Number of events and patients from Table 1 (calculated from
Equation (1) and Equation (3) respectively) which achieve 80% power for the first scenario of hazard ratios and significance levels are also presented.
Simulation Setting Number Simulated Power
Information
Fraction Group of Patients
Significance
Level Hazard Ratio
Required
Number of
Events
Required
Number of
Patients
Expected Total
Study Period
(Months)
Expected
Number of
Events
Expected Number
of Patients
Futility Stopping
Probability (FSP)
Efficacy Stopping
Probability (ESP) Power
25%
Biomarker-negative 0.0125 0.6 146 168 17.6 86 99 0.3694 0.1810 0.5659
Biomarker-positive 0.0125 0.4 45 76 16.9 25 43 0.3947 0.1894 0.5371
Entire population 0.025 - 191 244 - 111 142 - - -
Biomarker-negative 0.015 0.6 139 160 16.8 78 90 0.4172 0.1692 0.4999
Biomarker-positive 0.010 0.4 48 81 14.0 22 38 0.5071 0.2059 0.4257
Entire population 0.025 - 187 241 - 100 128 - - -
Biomarker-negative 0.010 0.6 154 177 14.9 77 88 0.4821 0.1886 0.4454
Biomarker-positive 0.015 0.4 43 72 16.1 23 39 0.4300 0.1885 0.4990
Entire population 0.025 - 197 249 - 100 127 - - -
50%
Biomarker-negative 0.0125 0.6 146 168 21.4 106 120 0.1650 0.4114 0.7259
Biomarker-positive 0.0125 0.4 45 76 21.4 32 54 0.1865 0.3859 0.6982
Entire population 0.025 - 191 244 - 138 138 - - -
Biomarker-negative 0.015 0.6 139 160 21.3 99 114 0.2044 0.3730 0.6697
Biomarker-positive 0.010 0.4 48 81 19.6 31 53 0.2670 0.4279 0.6146
Entire population 0.025 - 187 241 - 130 167 - - -
Biomarker-negative 0.010 0.6 154 177 20.2 103 119 0.2435 0.4126 0.6400
Biomarker-positive 0.015 0.4 43 72 21.0 30 50 0.2159 0.3873 0.6555
Entire population 0.025 - 197 249 - 133 169 - - -
75%
Biomarker-negative 0.0125 0.6 146 168 25.0 122 140 0.0704 0.5915 0.7743
Biomarker-positive 0.0125 0.4 45 76 24.9 37 63 0.0830 0.6036 0.7558
Entire population 0.025 - 191 244 - 159 203 - - -
Biomarker-negative 0.015 0.6 139 160 25.0 116 134 0.0943 0.5674 0.7266
Biomarker-positive 0.010 0.4 48 81 24.2 39 65 0.1330 0.6356 0.7185
Entire population 0.025 - 187 241 - 155 199 - - -
Biomarker-negative 0.010 0.6 154 177 24.5 126 145 0.1148 0.6204 0.7273
Biomarker-positive 0.015 0.4 43 72 24.9 36 60 0.1030 0.5708 0.7214
Entire population 0.025 - 197 249 - 162 205 - - -
J. Pers. Med. 2017, 7, 19 16 of 19
J. Pers. Med. 2017, 7, 19  17 of 22 
J. Pers. Med. 2017, 7, 19; doi:10.3390/jpm7040019  www.mdpi.com/journal/jpm 
 
Figure 5. Efficacy stopping probability, futility stopping probability and power of a two-stage design versus the interim fraction (25%, 50%, 75%) in each
biomarker-defined subgroup for scenario 1 of hazard ratios. Each row of graphs represents the different probabilities versus the interim fraction of each
biomarker-defined subgroup when (i) a− = a+ = 0.0125 (A,B), (ii) a− = 0.015 and a+ = 0.010 in (C,D), and (iii) a− = 0.010 and a+ = 0.015 in (E,F) respectively.
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Figure 6. Expected number of events and patients in two-stage design and required number of events and patients in one-stage design for each biomarker-defined
subgroup versus the hazard ratios of each biomarker-defined subgroup when the interim fraction is 25%. The first two graphical representations in each row of graphs
represent the number of events versus the hazard ratio of each biomarker-defined subgroup when (i) a− = a+ = 0.0125 in (A,B), (ii) a− = 0.015 and a+ = 0.010 in
(E,F), and (iii) a− = 0.010 and a+ = 0.015 in (I,J) respectively. The remaining graphical representations in each row of graphs represent the number of patients versus
the hazard ratio of each biomarker-defined subgroup when (i) a− = a+ = 0.0125 in (C,D), (ii) a− = 0.015 and a+ = 0.010 in (G,H), and (iii) a− = 0.010 and a+ = 0.015
in (K,L), respectively.
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3. Discussion
To conclude, we have considered a fixed design which evaluates the efficacy of treatment in each
biomarker-defined subgroup and an adaptive approach which involves early stopping of the trial
due to efficacy or futility. The scope of the simulation study of the fixed design is to investigate the
power under different scenarios in a given simulation setting which takes into account accrual and
follow-up of patients. Next, we extend the fixed design into a two-stage design with interim analysis
used for decision making. The aim of the two-stage version was to investigate the general efficiency of
the study by calculating the expected number of events and patients as well as stopping probabilities,
overall power and expected duration of the study under different scenarios of the information fraction
(i.e., specific proportion of the required total number of events applied in interim analysis). The tests
between the two biomarker-defined subgroups are independent and one could present the results for
only one of them. However, this could have added confusion regarding how control of the overall a is
handled. Additionally, presenting results for both subgroups adds completeness to our study.
We programmed the simulation studies in R statistical software (codes available upon request).
Our results indicate that when the information fraction used in interim analysis is low (25%) the study
will not achieve adequate power. However, for equally allocated significance levels we can achieve
sufficient power (between 70% and 80%) if the specific proportion of the required total number of
events is equal or greater than 50%.
One significant challenge encountered when conducting such flexible trial designs is the
multiplicity issues which should be carefully considered, e.g., in our simulation study we took into
account the control of type I error not only because we had to combine information from both stages of
the design but because we tested more than one subgroup of interest at the same time. Several methods
have been proposed recently for multiplicity adjustment and suggestions of appropriate stopping
boundaries when an interim analysis is introduced in the study design. Thus, the implications of the
operating characteristics to the decision-making when these methods are applied should be explored to
get the optimal results. Our simulation studies are limited to particular methods; however, they give us
a general insight into the implications of an event driven design for which the decision making is based
on the results of an interim analysis. We explore a fixed versus an adaptive approach in a popular
biomarker-guided clinical trial setting which to our best knowledge has not been investigated yet.
The adaptive version of the parallel subgroup-specific design could be extended by using the
sample size re-estimation approach [11]. More precisely, the idea behind this method is that at the
interim analysis—which in our case will be based on a fixed percentage of target events—we can allow
for re-evaluation of the sample size when there is uncertainty about the treatment effect size for which
the study was powered.
Knowledge of how to design, implement and analyse biomarker-guided clinical trials is essential
for testing the effectiveness of a biomarker-guided approach to treatment. The proper choice and use
of such designs can increase the probability of success of clinical trials resulting in the development of
novel treatments. Adaptive designs might be more complex and need more time during the planning
process due to several simulations of possible scenarios that should be conducted aiming to investigate
the statistical properties of the design under specific situations. However, they will continue to be an
attractive approach of clinical development as they can lead to potential reduction in cost and time
compared to a non-adaptive approach.
Supplementary Materials: The following are available online at http://www.mdpi.com/2075-4426/7/4/19 in
File S: Tables and graphical representations of simulation results, Tables S1–S4, Figures S1–S5.
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